About

Dr. Jody L Brown is an Associate Professor in the Department of Psychiatry at the University of Florida, specializing in Child and Adolescent Psychiatry. He joined the department in 2015 as a Clinical Associate Professor in the Division of Child and Adolescent Psychiatry and serves as the Program Director for the Child & Adolescent Fellowship program. Dr. Brown provides supervision to residents and fellows in the Child & Adolescent Psychiatry Clinic. His educational background includes an undergraduate degree from the University of Florida and an MD from the University of South Florida. He completed his General Psychiatry Residency and Child and Adolescent Psychiatry Fellowship at Wright-Patterson Air Force Base/Wright State University in Dayton, Ohio, from 1999 to 2004. During his military service, he was stationed at Barksdale Air Force Base and served as the U.S. Air Force Fellowship Training Director for Child & Adolescent Psychiatry, with deployments including Afghanistan. After his military service, Dr. Brown worked as a staff Child Psychiatrist at Halifax Behavioral Services and later joined the faculty at the University of Arkansas for Medical Sciences, where he served as Medical Director for various child psychiatry clinics and as Division Chief. He returned to Gainesville in 2014, working at Meridian Behavioral Healthcare before rejoining UF. His teaching profile includes courses such as Psychiatry Clerkship, and he holds board certifications in Child and Adolescent Psychiatry and Psychiatry from the American Board of Psychiatry and Neurology. His areas of interest include Attention Deficit Hyperactivity Disorder.

Research topics

• Medicine
• Computer Science
• Pharmacology
• Computer Security
• Machine Learning
• Family medicine
• Psychiatry
• Artificial Intelligence
• Internal medicine
• Political Science
• Immunology
• Psychology
• Bioinformatics
• Medical education
• Anesthesia
• Data science
• Biology
• Demography
• Chemistry
• Engineering
• Library science

Selected publications

• Examining Loneliness in People With Parkinson Disease Participating in Community-based Exercise

  Journal of Neurologic Physical Therapy · 2025-07-22

  article

  BACKGROUND AND PURPOSE: This study determined the prevalence of loneliness in a regional community-based exercise class program for people with Parkinson disease (PwPD) and examined relationships with demographic characteristics, functional independence, functional mobility, and quality of life (QOL). METHODS: This study was a cross-sectional analysis of 231 PwPD, all of whom were participating in community-based exercise class programs. Participants completed questionnaires on loneliness (UCLA 3-Item Loneliness Scale [UTILS]), functional independence (Schwab & England Scale), performance-based measures of functional mobility (Timed Up & Go, 10 Meter Walk Test, 30 Second Sit-to-Stand), and QOL (Parkinson's Disease Questionnaire-8). UTILS scores of ≤ 4 were classified as "non-lonely," and scores > 4 were classified as "lonely." RESULTS: Participants were, on average, 71.9 (±7.5) years old, 5.4 (±5.4) years since their Parkinson disease diagnosis, had been participating in group exercise classes for 2.3 (±2.4) years, and almost one-third of participants ( n = 76/231, 32.9%) scored in the "lonely" range on the UTILS. There were significant differences between the lonely and non-lonely groups in sex distribution, functional independence, Timed Up & Go, and QOL. Age, functional independence, and loneliness scores accounted for 55.8% of the variance in QOL scores. DISCUSSION AND CONCLUSION: In this study, loneliness was present even in PwPD actively engaged with an exercise community. Loneliness among PwPD was also related to functional independence, functional mobility, and QOL. While further study is needed, having rehabilitation clinicians and exercise class instructors screen for loneliness in PwPD may help inform plans of care and recommendations to address loneliness.

  PublisherDOI

• Capabilities and limitations of telemedicine in swine

  2025-02-15

  article
  PublisherDOI

• Treatment Outcomes in People with Migraine Receiving Rimegepant or Triptans: A Descriptive Analysis from a Real-World Survey (P1-12.008)

  Neurology · 2025-04-07

  article

  To assess treatment outcomes of people with migraine (PwM) who use rimegepant or triptans.

  PublisherDOI

• Expectation Violations Result in FC Changes with dACC Based on Cue: A PPI Analysis

  Journal of Pain · 2025-04-01

  articleSenior author
  PublisherDOI

• Successful Treatment of a Case of Flecainide-induced Ventricular Tachycardia Secondary to Acute Kidney Injury

  American Journal of Respiratory and Critical Care Medicine · 2025-05-01 · 1 citations

  article

  Abstract Introduction. Flecainide is a class IC anti-arrhythmic that is used in patients with atrial fibrillation who have structurally normal heart. However, It is known to be pro-arrhythmogenic in 3.5%-5% of patients. It could induce serious arrhythmias such as ventricular tachycardia (VT) likely due to excessive blockage of the sodium channels in the heart. Flecainide is metabolized by the liver and 30% of it is excreted by the kidneys. So, Acute kidney injury (AKI) is associated with flecainide toxicity. Case Presentation. A 73-year-old male presented to the emergency department with lethargy and lightheadedness after decreased oral intake for a few days. His past medical history is significant for atrial fibrillation (on flecainide and apixaban) and his last echocardiography (echo) was unremarkable. His blood pressure was 85/50 with oxygen saturation of 88% on room air. He had bilateral crackles on lung auscultation and bilateral lower limb edema. ECG showed VT. Investigations showed that he has AKI, lactic acidosis, and hyperkalemia with otherwise normal electrolytes and thyroid function tests. He received IV calcium gluconate, Insulin with dextrose, and IV sodium bicarbonate with persistent VT. He was successfully cardioverted and his blood pressure and oxygen saturation normalized immediately with significant improvement in his lactic acidosis. His AKI improved during his admission. His repeat echo was unremarkable. Discussion. This patient had decreased oral intake for a few days leading to pre-renal AKI. This AKI led to hyperkalemia and the accumulation of flecainide and its subsequent toxicity. Flecainide toxicity led to excess sodium channel blockade in the heart leading to VT. VT led to cardiogenic shock which resolved with cardioversion. His echo before and after the presentation was unremarkable. Conclusion. Clinicians should be aware of the arrhythmogenic effect of flecainide including the risk of VT. Flecainide should be suspended in patients with AKI to avoid toxicity. Flecainide-induced VT could be successfully treated with cardioversion.

  PublisherDOI

• The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey

  BMC Public Health · 2025-01-21 · 15 citations

  articleOpen access

  BACKGROUND: Despite the high global prevalence, burden, and direct and indicated costs, migraines are often under-diagnosed and undertreated. Understanding the prevalence of migraine and unmet needs is crucial for improving diagnosis and treatment across Europe (EU) countries; however, real-world studies are limited. METHODS: This retrospective cross-sectional survey utilized weighted patient-reported data from the 2020 National Health and Wellness Survey (NHWS) in five EU (5EU) countries (France, Germany, United Kingdom [UK], Italy, and Spain). The survey included adults aged ≥ 18 years who self-reported experiencing migraines in the past 12 months and had a physician's diagnosis. The survey assessed migraine prevalence by age and sex. Other measures included migraine characteristics, disability assessment, migraine frequency (monthly migraine days [MMDs] and monthly headache days [MHDs], menstrually-related migraine, treatment patterns, and provider characteristics. RESULTS: The study included 7,311 respondents with diagnosed migraines, representing an estimated 30.5 million adults with a weighted prevalence of 11.5% in the 5EU. Spain had the highest prevalence (14.0%), followed by Italy, France, UK, and Germany. Migraine prevalence was highest in the age group of 30-39 years, and females had nearly twice the prevalence compared to males. About 56% of respondents reported disability due to migraines, with highest percentage reported in Germany (66.0%). About 46% of female respondents reported experiencing menstrually-related migraines. One-fourth of the study respondents reported > 4 MMDs and 56.2% reported > 4 MHD. Current treatment patterns revealed that 79.7% of respondents were receiving some form of migraine treatment, with non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and triptans being the most commonly reported prescription medications. Primary care physicians (PCPs) were the most common providers diagnosing migraines, followed by neurologists. CONCLUSIONS: In the 5EU, one-fourth of diagnosed respondents reported > 4 MMDs, and 56.2% reported > 4 MHDs. Nearly half of females experienced menstrually-related migraines. Although most patients reported taking medication for migraine, severe disability and medication overuse were observed. PCPs were the main treatment providers, highlighting the need for improved expertise and referrals to specialists. Further research is required for a better understanding of the disparities between migraine frequency and treatment approaches.

  PublisherOA PDFDOI

• 449. Introducing Precuneus as a Novel Brain Target to Improve Cognitive Function and Emotion Regulation in PTSD

  Biological Psychiatry · 2025-04-09

  article
  PublisherDOI

• Measuring incremental burdens associated with increasing preventive-treatment failures among adults with migraine: a retrospective, cross-sectional study

  Therapeutic Advances in Neurological Disorders · 2025-06-08

  articleOpen accessSenior author

  Background: Migraine inflicts substantial personal, social, and economic tolls on many adults in the United States (US). Acute and preventive medicines can offer some relief, but most patients are untreated or experience treatment failures. How preventive-treatment failures affect outcomes for patients no longer on preventive treatments or for patients with migraine is insufficiently understood. Objective: To measure the patient-reported health and economic burdens associated with increasing preventive-treatment failures among US adults with diagnosed migraine. Design: Retrospective, cross-sectional study. Methods: Data analyzed were from the 2023 US National Health and Wellness Survey. Participants were adults diagnosed with migraine, having ≥4 monthly migraine or headache days, having taken acute or preventive prescription migraine medications or currently taking acute prescription migraine medications, and taking no preventive migraine medications. Participants were categorized as never treated with preventive medicines, having failed 1 preventive medicine, or having failed ≥2 preventive medicines. Health-related quality of life (HRQoL) was assessed with the Migraine Disability Assessment, RAND’s 36-Item Short Form Survey Instrument, 5-Level EuroQoL instrument (EQ-5D), Work Productivity and Activity Impairment General Health version, 9-Item Patient Health Questionnaire, and 7-Item Generalized Anxiety Disorder scale. Details about medication use and health care resource use (HCRU) were collected. Data were adjusted by inverse probability of treatment weighting and compared using two-sided two-sample t -tests or Chi-square tests. Results: Patients who had failed preventive treatments had poorer HRQoL, greater work productivity loss, greater nonwork activity impairment, and greater HCRU than patients who had never taken preventive treatments. The number of preventive-treatment failures scaled with disease burden. Patients with ≥2 treatment failures had significantly lower EQ-5D scores (0.69 vs 0.73) than those for prevention-naïve patients; patients with ≥2 treatment failures had significantly higher overall work productivity loss (45.9% vs 34.9%), activity impairment (46.8% vs 36.7%), and higher rates of emergency room visits (37.0% vs 25.2%), hospitalization (23.5% vs 12.3%), and neurologist visits (17.6 vs 10.9%) than those of prevention-naïve patients. Medication overuse rates were similar among patients with any treatment failures and prevention-naïve patients (migraine-specific: 34.4%-39.3%; overall: 59.2%-62.3%). Conclusion: US adults with frequent migraines who failed preventive treatments have significantly greater unmet needs and different acute medication use patterns than adults who never took treatments.

  PublisherDOI

• 290. Predictive Value of Subgenual Connectivity to TMS Treatment Site for Antidepressant Response in Routine Clinical Practice: A Prospective, Multisite Cohort Study

  Biological Psychiatry · 2025-04-09 · 1 citations

  article
  PublisherDOI

• Effects of iTBS on Synaptic Plasticity in the Presence of NMDA Receptor Modulators – Top Prospective Poster

  Transcranial magnetic stimulation . · 2025-04-01

  articleOpen accessSenior author
  PublisherOA PDFDOI

Frequent coauthors

• Amie Goodin

  156 shared

• Almut G. Winterstein

  Center for Drug Evaluation and Research

  99 shared

• Inmaculada Hernandez

  University of Montana

  83 shared

• Laura E. Happe

  University of Florida

  83 shared

• Elizabeth A. MacLean

  Pfizer (United States)

  82 shared

• Scott Mcdowell

  81 shared

• Elizabeth Burke

  James Madison University

  81 shared

• C. S.

  University of Nebraska Medical Center

  81 shared

Education

• B.S.

  University of Florida

• M.D.

  University of South Florida

• Other

  Wright-Patterson Air Force Base/Wright State University

  2004

• Other

  Wright-Patterson Air Force Base/Wright State University

  2004